Skip to the main content.
Contact Us

At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.

1 min read


April 16, 2015

New kits enables broader capture of tumor cells from blood using epithelial and mesenchymal markers

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluxion Biosciences announced the introduction of the IsoFlux™ EMT Enrichment Kit for the isolation of rare circulating tumor cells (CTCs) from blood samples. The new kit works with the IsoFlux System instrument and specifically targets cells with both epithelial and mesenchymal properties. This represents a breakthrough in liquid biopsy approaches since the mesenchymal properties have typically not been addressed in other capture systems. The IsoFlux EMT Enrichment Kits are available for immediate use through the IsoFlux Discovery Services program, with kit shipments to IsoFlux customers starting in the third quarter of 2015.

CTCs enable access to tumor material without the need for a surgical biopsy. They possess the key advantage of being able to be preferentially enriched over the background blood cells, making it possible to analyze them using molecular methods such as Next Generation Sequencing (NGS). Tumor cell recovery is linked to the capture antibodies chosen in the enrichment process. Epithelial Cell Adhesion Molecular (EpCAM) antibodies have long been the default capture marker, but it is understood now that CTCs lose their EpCAM expression as they transition to a mesenchymal state. The IsoFlux EMT Enrichment Kit incorporates the EpCAM antibody as well as a proprietary cocktail of EMT-specific antibodies to increase the overall capture of all types of CTCs. The initial analytical and clinical validation demonstrated notable increase in tumor cell capture.

“For several years now, the leading cancer scientists across the world have presented research on the dynamic changes in surface marker expression of cancer cells,” said Michael Schwartz, VP of Marketing at Fluxion. “We developed the IsoFlux EMT Enrichment Kit to provide a more comprehensive, turnkey solution for CTC capture that covers both epithelial and mesenchymal presentations.”

Like the other IsoFlux enrichment kits, the IsoFlux EMT Enrichment Kit includes the IsoFlux microfluidic cartridges, magnetic beads, running reagents, and proprietary cocktail of capture antibodies.

For more information, please visit:

About Fluxion Biosciences
Fluxion Biosciences provides cellular analysis tools for use in critical life science, drug discovery, and diagnostic applications. Products include the BioFlux™ System for studying cellular interactions, the IonFlux™ System for high throughput patch clamp measurements, and the IsoFlux™ System for circulating tumor cell analysis. Fluxion’s systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. For more information about Fluxion Biosciences, visit